News Conference News SCCT 2024 AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk Todd Neale July 25, 2024
News Conference News ACC 2024 Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI Yael L. Maxwell April 06, 2024
News Conference News SCCT 2023 Population Screening for Coronary Plaque: Is the Evidence Enough? Todd Neale July 31, 2023
News Daily News Statins Positively Alter Coronary Plaque Composition Michael O'Riordan August 23, 2021
News Daily News Web-Like Structures in COVID-19 STEMI Clots May Offer New Drug Target L.A. McKeown January 04, 2021
News Daily News ‘Super-Dense’ Calcified Plaque Appears Protective Against ACS Michael O'Riordan January 24, 2020
News Conference News SCCT 2019 Retrospective Study Validates CAC-DRS Score for Predicting Mortality Yael L. Maxwell July 23, 2019
News Daily News Atherosclerosis Features Differ Among Male Athletes From Different Sports Todd Neale February 18, 2019
News Industry News AUM Cardiovascular Receives FDA Approval For Revolutionary Diagnostic Heart Device August 08, 2017
News Daily News ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation Yael L. Maxwell June 29, 2017
News Industry News Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) September 20, 2016
News Industry News FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor July 11, 2016
News Daily News Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela Todd Neale June 22, 2016
News Daily News Mammogram-Derived Clues to Cardiovascular Disease Often Unreported and Ignored L.A. McKeown March 25, 2016
News Industry News Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union September 28, 2015
News Industry News Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab) September 11, 2015
News Industry News Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection July 09, 2015